SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 30, 2005
Dragon Pharmaceutical, Inc.
(Exact name of registrant as specified in its charter)
Florida 0-27937 65-0142474
------- ------- ----------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification No.)
1055 West Hastings Street, Suite 1900
Vancouver, British Columbia
Canada V6E 2E9
(Address of principal executive offices)
(604) 669-8817
(Issuer's telephone number)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Section 5 - Corporate Governance and Management
Item 5.02 Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers.
(d) On September 30, 2005, the Board of Directors of Dragon Pharmaceutical
appointed Mr. Peter Mak, Mr. Heinz Frey, and Mr. Jin Li to the board. Their
business experience and qualifications are set forth below.
Mr. Peter Mak, age 44, is a fellow of the Chartered Association of Certified
Accountants in UK as well as a fellow of the Hong Kong Institute of Certified
Public Accountant. Mr. Mak was formerly the Managing Partner of Arthur Andersen
Southern China and also a partner of Arthur Andersen Worldwide. Through his
twenty years of accounting and financial practices, Mr. Mak has extensive
knowledge and experience in Chinese and international accounting standards. In
addition, Mr. Mak is the Chief Financial Officer of New Dragon Asia Corp., whose
shares are registered under the Securities Exchange Act of 1934.
Mr. Heinz Frey, age 67, graduated from University of Berne/Switzerland in 1966,
has 30 years of experience in the telecommunication industry, security
manufacturing and service industry. He has broad experience in the management of
various sizes of companies with global presence, financing and controlling of
international companies, leading development, production, sales and finance
departments. He is also a board member of various companies.
Mr. Jin Li, age 38, is currently a senior advisor of Phycos International Co.,
Ltd. Prior to joining Phycos, he was a partner at the international law firm,
Linklaters. Mr. Li studied biochemistry at Peking University in China and
received his Master of Science degree in Biochemistry from the University of
Michigan and his doctoral degree from Law School of University of Columbia. He
has more than ten years of experience in international IPOs, M&A and business
transactions.
Concurrent upon the appointment of the three new independent directors, the
Board of directors established an Audit Committee and Compensation Committee.
Mr. Peter Mak was elected as the Chairman of Audit Committee with Mr. Heinz Frey
and Mr. Jin Li as members. Ms. Xuemei Liu was elected as the Chairman of the
Compensation Committee with Dr. Yiukwong Sun and Jin Li as members.
A copy of the press release announcing the naming the three new directors and
their new committee assignments is included herewith as an exhibit to this
report.
Section 9. Financial Statements and Exhibits.
Item 9.01 Financial Statements and Exhibits
(c) Exhibit 99.1
Press release dated September 30, 2005.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: October 4, 2005 Dragon Pharmaceutical, Inc.
a Florida Corporation
/s/ Maggie Deng
----------------------------------------
Maggie Deng, Chief Operating Officer